Rapid Micro Biosystems, a leading provider of automated, non-destructive, rapid microbial detection for quality control testing within the pharmaceutical, personal care products and medical device market segments, today announced that it has raised $25 million in Series C equity financing. The financing will be used to expand global commercial and manufacturing operations in support of the industry leading Growth DirectTM System across the applications of environmental monitoring, sterility and bioburden testing. The round included financing from new investors, Hepalink USA…